Spyre Spyre治疗法击败了Q3损失估计,尽管损失仍在继续,但2025年的前景仍然有所改善。 Spyre Therapeutics beat Q3 loss estimates, boosting 2025 outlook despite ongoing losses.

Wedbush和Leerink Partners的分析师订正了Spyre治疗学2025年收入前景向上,现在预测每股损失2.11美元至2.6美元,指出尽管不断亏损,但预期的财务情况有所改善。 Analysts at Wedbush and Leerink Partners revised Spyre Therapeutics' 2025 earnings outlook upward, now forecasting a loss of $2.11 to $2.60 per share, citing improved financial expectations despite ongoing losses. 该公司报告说,2025年Q3每股损失0.15美元,击败估计数为0.53美元。 The company reported a Q3 2025 loss of $0.15 per share, beating estimates by $0.53. Spyre是针对炎症肠病开发的SPY001临床先期生物技术,市场上限为13.5亿美元,股票价格约为22.39美元。 Spyre, a preclinical biotech developing SPY001 for inflammatory bowel disease, has a market cap of $1.35 billion and a stock price around $22.39. 虽然有些公司维持“销售”评级,但总体共识仍然是“购买”,平均价格目标为52.50美元。 While some firms maintain a "sell" rating, the overall consensus remains "buy" with a $52.50 average price target.